The effect of the trifunctional anti-EpCAM antibody catumaxomab on the development of tumor-specific immune responses in patients with gastric cancer.

被引：1
|
作者：
Reinhard, H.
Meyer, S. K.
Bartels, K.
Fischer, R.
Seimetz, D.
Bokemeyer, C.
Atanackovic, D.
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Univ Canc Ctr Hamburg, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Univ Canc Ctr, Hamburg, Germany
[3] Fresenius Biotech GmbH, Munich, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.2601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2601
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Effect of catumaxomab on EpCAM plus tumor cells in vitro in the presence of immune effector cells from ovarian cancer patients treated with chemotherapy
    Pietzner, K.
    Sehouli, J.
    Atz, J.
    Dettmar, K.
    Martinius, H.
    Spannagl, R.
    Seimetz, D.
    Schroeder, P.
    Lindhofer, H.
    Oskay-Oezcelik, G.
    Chekerov, R.
    Braicu, E. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] An evaluation of anti-EpCAM x anti-CD3 bispecific antibody using patients derived cancer organoids.
    Tsumura, Ryo
    Komatsu, Teruo
    Koga, Yoshikatsu
    Yasunaga, Masahiro
    CANCER SCIENCE, 2025, 116 : 300 - 300
  • [33] Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.
    Qi, Changsong
    Wu, Shikai
    Kim, In-Ho
    Cai, Shirong
    Wang, Jufeng
    Kim, Seung Tae
    Wang, Jaw-Yuan
    Bai, Li-Yuan
    Lin, Cheng-Yao
    Liang, Zhezhao
    Wei, Jian Xin
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16102 - E16102
  • [34] A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy
    Frey, Gerhard
    Cugnetti, Ana Paula G.
    Liu, Haizhen
    Xing, Charles
    Wheeler, Christina
    Chang, Hwai Wen
    Boyle, William J.
    Short, Jay M.
    MABS, 2024, 16 (01)
  • [35] Characterization of immune responses in gastric cancer patients:: A possible impact of H-pylori to polarize a tumor-specific type 1 response?
    van den Engel, Natasja K.
    Winter, Hauke
    Ruettinger, Dominik
    Shau, Irene
    Schiller, Matthias
    Mayer, Barbara
    Moudgil, Tarsem
    Meimarakis, Georgios
    Stolte, Manfred
    Jauch, Karl-Walter
    Fox, Bernard A.
    Hatz, Rudolf A.
    CLINICAL IMMUNOLOGY, 2006, 120 (03) : 285 - 296
  • [36] Randomized, multicenter, two-dose level, open-label, phase IIA study with theintraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EPCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients
    Burges, A.
    Pfisterer, J.
    Wimberger, P.
    Kurzeder, C.
    du Bois, A.
    Sehouli, J.
    Loibl, S.
    Burchardi, N.
    Vergote, I.
    Wagner, U.
    ONKOLOGIE, 2008, 31 : 102 - 102
  • [37] Trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): Interim analysis of a phase I study
    Antoniewicz, A. A.
    Albert, F.
    Wessels, F.
    Lenhart, M.
    Neuberger, M.
    Ruf, P.
    Lindhofer, H.
    Oberneder, R.
    Kriegmair, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1160 - S1160
  • [38] Hormone and radiation therapy induce tumor-specific immune responses in prostate cancer
    Sahota, Rob A.
    Nesslinger, Nancy J.
    Ludgate, Charles
    Pai, Howard
    Blood, Paul
    Chima, Navraj
    Johnson, Kayli
    Nelson, Brad H.
    CANCER RESEARCH, 2006, 66 (08)
  • [39] Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses
    Murthy, Vivek
    Minehart, Janna
    Sterman, Daniel H.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (12):
  • [40] Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients
    Belau, A.
    Pfisterer, J.
    Wimberger, P.
    Kurzeder, C.
    Du Bois, A.
    Sehouli, J.
    Loibl, S.
    Burchardi, N.
    Vergote, I.
    Wagner, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345